The fight over compounded peptides just gained its most powerful opponent.
On November 9, at its interim meeting in the Orlando area, the American Medical Association adopted a policy urging the Department of Health and Human Services, the FDA and other federal regulators to reverse directives that ease restrictions on compounding synthetic peptides that have not received FDA approval.
The AMA’s announcement did not identify a particular federal notice by name. But the timing and subject leave little doubt about the immediate policy at issue.
Less than two weeks earlier, HHS published an interim enforcement policy covering six unapproved peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500.
Under specified conditions, the department said it would not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding products made with those substances while FDA rulemaking continues.
Now the country’s largest physician organization wants federal officials to reverse that approach. It also wants state medical and pharmacy boards involved in enforcement against sellers of unapproved peptide formulations.
The timing is pointed. Written comments on the HHS policy close at 11:59 p.m. Eastern on November 13, 2026, under docket HHS-OASH-2026-0496.
The dispute is no longer just about what FDA scientists believe the evidence supports. It is about who gets to set the enforcement posture while the regulatory decision remains unfinished.
What HHS Actually Did With Compounded Peptides
The HHS action was filed for public inspection on October 28 and published in the Federal Register on October 30, 2026.
Signed by Health Secretary Robert F. Kennedy Jr., the notice announced the availability of an interim enforcement-discretion policy under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Section 503A governs certain drugs compounded by licensed pharmacists and physicians for individual patients. To qualify for statutory exemptions, products made from bulk drug substances must satisfy specified requirements, including rules governing which ingredients may be used.
The six peptides covered by the HHS policy have not been added to the FDA’s 503A bulks list through final rulemaking.
That distinction matters. HHS is changing how it intends to exercise federal enforcement discretion in defined circumstances, not changing the underlying statutory status of those ingredients.
According to the published HHS policy, the department does not intend to take enforcement action against covered compounders when ten specified conditions are satisfied.
The requirements include patient-specific prescriptions, identification and testing of ingredients, manufacturing-source documentation, reporting serious adverse events and product-quality problems, and restrictions on the formulations and routes of administration.
Products must contain only one active pharmaceutical ingredient from the policy’s covered list. The document does not extend its enforcement discretion to unrestricted combinations of multiple listed peptides.
The policy also specifies which chemical forms and administration routes are covered. For example, it addresses intranasal Semax, while other substances have different listed routes.
HHS states that products within the policy remain compounded drugs, not FDA-approved medicines. FDA has not reviewed those finished products through the drug-approval process for safety, effectiveness or quality before marketing.
And the document explicitly states that it creates no enforceable rights and is not binding on HHS or the public.
An enforcement pause is not an approval. It is a statement about when federal officials currently intend not to act.
The department reserves the ability to revisit its position if safety signals or product-quality problems emerge. Future FDA rulemaking may ultimately include or exclude individual substances from the 503A bulks list.
Grey Pepper examined the original decision in its report on HHS’s six-peptide enforcement-discretion policy.
The Expert Split Behind the HHS Policy
The scientific record behind the decision is unusually divided.
On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptide substances nominated for inclusion on the 503A bulks list.
The committee voted in favor of recommending six: BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon.
The seventh substance, emideltide, also called delta sleep-inducing peptide or DSIP, did not receive a favorable recommendation.
Those votes were narrow in several cases. They were also advisory rather than binding decisions about what pharmacies could legally compound.
FDA scientists at the Center for Drug Evaluation and Research had recommended against placing the substances on the list, citing unresolved concerns about safety, characterization and the adequacy of supporting evidence.
Despite those scientific recommendations, the advisory committee supported the six substances later included in HHS’s interim policy.
HHS then adopted a different regulatory approach. Rather than waiting for final rulemaking, the department announced conditional enforcement discretion for those six peptides.
That produced three different positions on the same group of substances.
The FDA’s scientific reviewers recommended against listing them. The agency’s outside advisory committee favored inclusion. HHS chose limited enforcement forbearance while the formal process continues.
Those are not three competing determinations of clinical safety. They are different scientific recommendations and regulatory judgments made at different stages of the process.
HHS has offered its own rationale for the interim policy.
The department argues that allowing limited compounding under defined safeguards may offer patients a more controlled alternative to research-use-only peptides obtained from suppliers that do not provide comparable assurance of identity, purity and quality.
Its published document also cites historical-use information and additional substance-characterization evidence that HHS considers relevant to the temporary decision.
That is an access and risk-management argument, not proof that any of the six peptides has demonstrated clinical effectiveness for a particular disease.
Opponents argue that improving manufacturing controls does not resolve inadequate human safety or efficacy evidence. A well-characterized product can still expose patients to biological risks that have not been adequately studied.
The disagreement therefore extends beyond whether patients should have access. It concerns how much uncertainty regulators should tolerate before access is expanded.
For more on the advisory process, see Grey Pepper’s earlier article explaining why an FDA advisory committee vote is not drug approval.
What the AMA Is Actually Asking For
The AMA’s November 9 announcement makes two regulatory demands and one educational commitment.
First, the association wants HHS, the FDA and other relevant federal authorities to immediately rescind directives easing restrictions on compounding and distributing unapproved synthetic peptides.
Second, it wants to collaborate with federal regulators, state medical boards and state boards of pharmacy to pursue strict oversight and enforcement against compounding pharmacies, direct-to-consumer telehealth platforms and online dispensaries distributing unapproved peptide formulations.
Third, it wants physicians, other healthcare professionals and patients educated about the risks, the lack of adequate clinical efficacy evidence and the regulatory limitations of these products.
The position grew out of a resolution introduced by the Obesity Medicine Association at the AMA’s 2026 Interim Meeting.
The adopted position addresses unapproved synthetic peptides broadly rather than creating a regulatory prohibition limited to the six substances named in the HHS policy.
AMA board member Ilse R. Levin framed the association’s concern in patient-safety terms, warning that expanded compounding without sufficient evidence and oversight could expose patients to serious, preventable harm.
The association’s position is not based on a newly published clinical trial showing that all six peptides cause the same harm.
It is based on the broader problem of incomplete evidence, unresolved safety questions and the absence of FDA approval for the products being discussed.
That distinction matters because the regulatory argument should not be mistaken for a finding that every peptide is equally dangerous.
The substances have different biological targets, proposed uses and evidence bases. Some have limited human research, while others rely heavily on laboratory and animal studies. None of the six has received FDA approval through the conventional drug-approval pathway for the uses associated with this policy.
Supporters of controlled access argue that qualified prescribers and regulated compounders could be preferable to leaving patients to buy poorly characterized materials from unregulated suppliers.
The AMA takes the opposite regulatory position: without sufficient clinical evidence, a more controlled distribution channel does not itself justify easing enforcement.
The AMA is not just objecting to the federal policy. It is proposing a role for state regulators in the enforcement response.
Why State Medical and Pharmacy Boards Are the Pressure Point
The second half of the AMA policy may have greater practical consequences for pharmacies and telehealth businesses than its call for rescission.
HHS can announce how it intends to exercise federal enforcement discretion. State medical and pharmacy boards, however, have their own licensing and disciplinary powers under applicable state laws.
A federal decision not to pursue certain enforcement actions does not automatically prevent a state regulator from investigating conduct that independently violates state requirements.
State pharmacy boards may regulate pharmacy licensing, inspections, compounding standards and professional conduct. State medical boards may act against physicians who violate applicable professional or prescribing rules.
That creates a layered regulatory environment.
A compounder may seek to satisfy all the conditions described in HHS’s interim policy but still need to determine whether its activities comply with the laws and requirements of the states where it operates and supplies patients.
For telehealth businesses operating across multiple states, that analysis becomes especially complicated.
Prescribing, dispensing, pharmacy licensure and professional oversight can involve different regulators and obligations depending on the jurisdiction.
The AMA’s adopted policy specifically names compounding pharmacies, direct-to-consumer telehealth platforms and online dispensaries as potential enforcement targets.
That wording is significant, although it does not establish that any particular business has violated the law.
Nor can the AMA itself order a state board to discipline a licensed professional.
The organization can advocate, coordinate and encourage enforcement, but individual boards must act within their own statutory authority and procedures.
Still, the political message is clear. Even if HHS maintains its interim policy, organized medicine intends to press regulators operating outside the federal enforcement decision.
The market therefore cannot treat federal enforcement discretion as a blanket permission slip.
The Patient-Safety Objections Are Not New
The AMA’s intervention adds institutional weight to objections already raised during the FDA advisory process.
As Becker’s Hospital Review reported, the patient-safety organizations ECRI and the Institute for Safe Medication Practices had previously warned against relaxing restrictions on the substances.
Patients who attribute adverse experiences to peptide products have also argued that their concerns are being overlooked during the access debate.
Those accounts deserve investigation, but anecdotal reports alone do not establish the frequency or cause of adverse effects across a broader population.
That is part of the difficulty regulators face.
Without sufficiently large, well-controlled human studies, it is difficult to estimate benefits, characterize uncommon adverse events, establish appropriate dosing or compare long-term risks.
Additional manufacturing safeguards can reduce some quality-related uncertainties, but they cannot substitute for clinical evidence about what a substance does inside the human body.
HHS’s policy attempts to address product-characterization and oversight concerns through testing, traceability, reporting and formulation restrictions.
The AMA is arguing that these safeguards do not resolve the threshold problem of insufficient evidence for routine clinical use.
Both positions acknowledge risk. They differ over whether limited supervised access or continued restrictive enforcement is the more appropriate response while scientific uncertainty remains.
What the AMA Policy Cannot Do
The limits of the AMA’s decision are important.
An AMA resolution is an organizational policy position, not a federal law or regulation.
It cannot independently rescind HHS’s enforcement policy, remove a substance from a regulatory list or impose new legal duties on pharmacies.
HHS is not required to adopt the association’s position.
Any federal policy reversal would require action by the relevant government authorities. State enforcement would likewise depend on applicable law and regulatory decisions.
There is also no public evidence in the sources reviewed here that the AMA’s announcement itself has already caused the federal policy to be withdrawn.
As of November 12, the October 30 HHS notice remains the published federal policy document, with the public comment window approaching its scheduled close.
Grey Pepper also could not establish how many pharmacies have begun operating under the interim policy or how consistently its manufacturing and reporting conditions are being met.
Nor does the available record quantify the number of patients who might gain or lose access under either regulatory approach.
Those uncertainties limit claims about the policy’s actual effects.
It would be premature to say the HHS action has already produced a measurable safety improvement or a measurable increase in harm.
It would be equally premature to assume the AMA’s opposition guarantees a reversal.
What Happens After the November 13 Deadline
The immediate calendar is straightforward.
HHS is accepting written comments on its interim enforcement policy through November 13, 2026.
The official docket is HHS-OASH-2026-0496, and the notice was published in the Federal Register as document 2026-22192.
The close of that comment window does not automatically terminate the interim policy or decide whether the six peptides belong on the 503A bulks list.
Those listing decisions require further regulatory consideration and rulemaking.
HHS has stated that future FDA rulemakings may propose adding some or all of the substances to the list based on the available evidence.
Each substance may ultimately receive a different regulatory outcome. The six peptides do not have to succeed or fail as one group.
There is also more work ahead for the Pharmacy Compounding Advisory Committee. As of July, additional unapproved peptides were scheduled for review in February 2027.
The AMA’s decision introduces another pressure point before those reviews take place.
If HHS preserves its existing approach, the question becomes how federal enforcement discretion will coexist with state regulation and continued scientific scrutiny.
If the department reverses course, compounders and prescribers may face a different immediate enforcement environment even before formal listing decisions are completed.
For pharmacies, the practical issue is whether they can rely on a temporary federal position that the department can revisit.
For physicians, it is whether the available evidence and applicable professional obligations justify prescribing products that have not undergone FDA drug approval.
For patients, it is whether expanding supervised access produces a better balance of potential benefit and risk than leaving demand to a market with variable oversight.
And for regulators, the unresolved question is who should determine acceptable uncertainty while the scientific and legal reviews continue.
The AMA has now made its preference clear.
It wants the federal government to reverse the easing of restrictions, and it wants state boards to remain active in overseeing the market.
The HHS policy changed the federal enforcement posture. The AMA’s response shows that the fight over compounded peptides is far from settled.
Disclosure
Grey Pepper’s owner also has business interests in the research-peptide market. This relationship is disclosed because regulatory decisions concerning peptides may affect that market.
Sources and Further Reading
- American Medical Association. AMA adopts new policies to protect patients and strengthen public health. November 9, 2026.
- American Medical Association. Highlights from the 2026 AMA Interim Meeting. Updated November 10, 2026.
- US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026. Docket HHS-OASH-2026-0496.
- US Department of Health and Human Services. Full Enforcement Discretion Policy, including Appendix A and Appendix B and the ten conditions for covered compounding.
- US Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting, agenda and supporting materials.
- The American Journal of Managed Care. Five Things to Know About HHS’s Interim Peptide Compounding Policy. October 29, 2026.
- Becker’s Hospital Review. New AMA Policy Targets Unapproved Peptide Compounding. November 10, 2026.
- Venable LLP. In-Depth Analysis: HHS Announces Interim Enforcement Discretion for Section 503A Compounding With Certain Peptide Bulk Drug Substances. November 6, 2026.
- Regulations.gov. HHS-OASH-2026-0496: Official public comment docket. Comment deadline: November 13, 2026.
